AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01359618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single dose, oral tablets
Study NCT01359618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: Single dose, oral tablets
Study NCT01359618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo comparator
Description: Single dose, oral tablets
Study NCT01359618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Single dose, oral tablets
Study NCT04584879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard UP Treatment
Description: Participants will receive treatment modules sequenced in accordance with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP; Barlow et al 2011; 2018).
Study NCT04584879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capitalization UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that capitalize on patient strengths.
Study NCT04584879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensation UP Treatment
Description: Participants will receive Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) treatment modules organized to prioritize skills that compensate for patient weaknesses.
Study NCT02316392 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized Helium-3 MRI
Description: Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
Study NCT01919177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate rich beetroot juice
Description: Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
Study NCT01919177 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate depleted beetroot juice
Description: Subjects will receive 140 mL of nitrate-depleted beetroot juice.
Study NCT03821064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (\~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
Study NCT03494985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Oralbalance Moisturizing Gel
Description: Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
Study NCT03494985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Original Oral Rinse
Description: Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
Study NCT03494985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene Moisturizing Mouth Spray
Description: Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
Study NCT03494985 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
Study NCT02480751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost
Study NCT02480751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06297031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: heat application
Description: • Thermophore Application: Before the application, the thermophore was wrapped in a towel to prevent skin damage. Studies in the literature indicate that the surface temperature of the thermophore should be 38-45 °C. For this reason, water with a temperature of 70°C when measured with a thermometer was added into the thermophore. Similarly, studies in the literature indicate that thermophore application should be applied for 10-30 minutes. Therefore, the application takes 20 minutes. The researcher stayed with the woman for 20 minutes.
Study NCT04359264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: Cash transfer of $1000
Study NCT03383575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT03383575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO
Study NCT03383575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03654105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects.
Study NCT03654105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: The treatment will consist of Acetylsalicylic acid at 100mg once a day
Study NCT01701128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on treadmill
Description: 3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
Study NCT01701128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on treadmill
Description: 3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
Study NCT01701128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
Study NCT00870922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active release techniques
Description: Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
Study NCT02518685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TransPyloric Shuttle
Study NCT02518685 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Study NCT02518685 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle Counseling
Description: The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
Study NCT03654105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Modification and Physical Activity Increase
Description: It will be proposed:~1. an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~2. a regular and sustainable physical activity program with periodic verification of the results.
Study NCT03654105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: early lung cancer detection
Description: standard treatment for early lung cancer detection with ultra low dose CT
Study NCT03654105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: early lung cancer detection
Description: standard treatment for early lung cancer detection with ultra low dose CT
Study NCT03654105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spirometry with CO test
Description: spirometry with CO test
Study NCT02456259 — intervention group
Intervention type: PROCEDURE
Intervention: Neck cannula insertion
Description: Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
Study NCT03654105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: spirometry with CO test
Description: spirometry with CO test
Study NCT03654105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anthropometic data collection
Description: anthropometic data collection
Study NCT03654105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: anthropometic data collection
Description: anthropometic data collection
Study NCT03654105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test
Description: blood test to assess the metabolic and inflammatory profile
Study NCT03654105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood test
Description: blood test to assess the metabolic and inflammatory profile
Study NCT04592627 — intervention group
Intervention type: OTHER
Intervention: Simulated home environment visit
Description: During the simulated home environment visit participants will 1) participate in a simulated University of Texas (UT) Physicians Stroke Outpatient Clinic telemedicine visit using an iPAD during which participants will be audio- and visually-recorded in order for the research team to collect raw facial expression data; 2) be instructed to complete a series of activities of daily living (e.g., sitting down and brushing hair) during which participants will be audio- and visually-recorded in order for the research team to collect raw body motion tracking data; and 3) complete a participant satisfaction survey via a REDCap link and participate in an audio-recorded, semi-structured interview (e.g., asking the participants thoughts on privacy considerations related to future use of the facial expression and body motion technology in a home environment) with members of the research team.
Study NCT03453281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
Study NCT04383340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother-Infant Transaction Program
Description: Parent sensitivity training for mothers of premature infants
Study NCT01420900 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with ABG II / Trident
Description: Surgery with total hip arthroplasty in the form of ABG II / Trident
Study NCT01420900 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with CLS / Trilogy
Description: Surgery with total hip arthroplasty in the form of CLS / Trilogy
Study NCT03648684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caffeine-Based Expectancy Challenge
Description: Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
Study NCT03648684 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Based Expectancy Challenge
Description: Intervention to alter expectancies (expectancy modification only)
Study NCT00439361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.0 mg/m\^2 by Vein Over 5 Seconds on Days 1 and 4
Study NCT00439361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 5 AUC by Vein Over 1 Hour On Day 1
Study NCT00439361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 By Vein Over 2 Hours On Days 1-3
Study NCT00439361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 5 Gm/m\^2 By Vein Continuous Infusion Over 24 Hours On Day 1
Study NCT00439361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 5 mg/m\^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m\^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
Study NCT02934893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Management Clinic
Description: referral to medication management clinic from primary care
Study NCT02934893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Management Clinic
Description: referral to medication management clinic from primary care
Study NCT02934893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes+Me plus connected glucometer
Description: Use of software and medication modeling tool as add on to medication management standard of care
Study NCT00731588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfused Biotin RBCs - Adults Phase I
Description: A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns \~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
Study NCT00731588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfused Biotin RBCs - Infants Phase II
Description: After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
Study NCT00731588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfused Biotin RBCs - Infants Phase III
Description: Phase III (infants) to be determined upon completion of Phase II (infants).
Study NCT00710814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
Study NCT00710814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leptin
Description: Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
Study NCT00710814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
Study NCT00710814 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
Study NCT01913288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological Maternal Sounds
Study NCT01913288 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Biological Maternal Sounds
Study NCT02518685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
Study NCT00193778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery for breast cancer
Description: This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
Study NCT00193778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Loco-regional treatment
Description: This group will not receive any loco-regional treatment
Study NCT00601354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation group therapy
Description: Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
Study NCT00601354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat/alli program
Description: The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
Study NCT00601354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat/alli program
Description: The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
Study NCT04812587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention program
Description: The experimental group will receive a 12-week combined exercise intervention program with extra emphasis on balance, muscle strength, and walking ability which involved two 2-hour sessions once per week.
Study NCT03368989 — intervention group
Intervention type: DRUG
Intervention: Radium-223 dichloride
Description: Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.
Study NCT05572411 — intervention group
Intervention type: OTHER
Intervention: GAITRite Electronic Walkway
Description: Participants will be asked to walk across the electronic walkway to record information relating to their gait pattern. Depending on the age and compliance of the participant, they will be asked to complete 3 passes at 3 speeds, preferred, fast and slow.
Study NCT00434161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin before only
Description: One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 \& 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
Study NCT00434161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing.
Study NCT00434161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin before and after
Description: One bolus IV injection at 60 μg/kg/day, on Days 6, 5 \& 4 (before-high dose chemotherapy) and on Days 0, 1 \& 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
Study NCT00279448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: On tablet of 25 mg per day during 5 years
Study NCT00279448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen
Description: Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
Study NCT03168074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.